Phase III clinical trials of atezolizumab in combination with chemotherapy in chemotherapy-naive patients with advanced NSCLC

被引：0

作者：

Mok, T. S. K. ^{[1
]}

Cappuzzo, F. ^{[2
]}

Jotte, R. M. ^{[3
]}

Reck, M. ^{[4
]}

Papadimitrakopoulou, V. ^{[5
]}

Sandler, A. ^{[6
]}

Waterkamp, D. ^{[6
]}

Verret, W. ^{[6
]}

Shen, Y. ^{[7
]}

Socinski, M. A. ^{[8
]}

机构：

[1] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China

[2] Osped Civile, Ist Toscano Tumori, Livorno, Italy

[3] Rocky Mt Canc Ctr, Med Oncol, Denver, CO USA

[4] Lung Clin Grosshansdorf, Dept Thorac Oncol, Grosshansdorf, Germany

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Genentech Inc, Clin Sci, San Francisco, CA 94080 USA

[7] Genentech Inc, Biostat, San Francisco, CA 94080 USA

[8] Univ Pittsburgh, Med Ctr, Div Hematol Oncol, Pittsburgh, PA USA

来源：

ANNALS OF ONCOLOGY | 2015年 / 26卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

356TiP

引用

页码：106 / 106

页数：1

共 50 条

[41] A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive Castrate Resistant Prostate Cancer (CRPC)
Beardsley, E. K.
Hotte, S. J.
Ellard, S.
Winquist, E.
North, S.
Chi, K. N.
EJC SUPPLEMENTS, 2009, 7 (02): : 410 - 410
[42] A randomized phase III trial comparing bexarotene/carboplatin/paclitaxel versus carboplatin/paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC).
Blumenschein, GR
Khuri, F
Gatzemeier, U
Miller, WH
von Pawel, J
Rigas, JR
Herbst, RS
Dziewanowska, Z
Negro-Vilar, A
Mabry, M
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 1094S - 1094S
[43] Phase III results of exatecan (DX-8951f) versus gemcitabine (Gem) in chemotherapy-naive patients with advanced pancreatic cancer (APC)
Cheverton, P
Friess, H
Andras, C
Salek, T
Geddes, C
Bodoky, G
Valle, J
Humblet, Y
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 314S - 314S
[44] Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer
Yang, Zu-Yao
Liu, Li
Mao, Chen
Wu, Xin-Yin
Huang, Ya-Fang
Hu, Xue-Feng
Tang, Jin-Ling
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (11):
[45] CLINICAL TRIALS AND COMBINATION CHEMOTHERAPY
CARTER, SK
CANCER CHEMOTHERAPY REPORTS PART 3, 1971, 2 (01): : 81 - &
[46] Randomized phase II study of erlotinib (E) or intercalated E with carboplatin/paclitaxel (CP) in chemotherapy-naive advanced NSCLC: Correlation of biomarker status and clinical benefit
Hirsch, F. R.
Dziadziuszko, R.
Varella-Garcia, L.
Franklin, W.
Bunn, P.
Kabbinavar, F.
Wacker, B.
Rusk, J.
Richardson, K.
Camidge, D. R.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[47] Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial
Zurita, A. J.
George, D. J.
Shore, N. D.
Liu, G.
Wilding, G.
Hutson, T. E.
Kozloff, M.
Mathew, P.
Harmon, C. S.
Wang, S. L.
Chen, I.
Maneval, E. Chow
Logothetis, C. J.
ANNALS OF ONCOLOGY, 2012, 23 (03) : 688 - 694
[48] Combination of radiotherapy and chemotherapy in locally advanced NSCLC
Kepka, Lucyna
Sprawka, Arkadiusz
Casas, Francesc
Abdel-Wahab, Sherif
Agarwal, Jai Prakash
Jeremic, Branislav
EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (10) : 1389 - 1403
[49] A randomized phase III trial comparing ionafarnib/carboplatin/paclitaxel versus carboplatin/paclitaxel (CP) in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC)
Blumenschein, G
Ludwig, C
Thomas, G
Tan, E
Fanucchi, M
Santoro, A
Crawford, J
Breton, J
O'Brien, M
Khuri, F
LUNG CANCER, 2005, 49 : S30 - S30
[50] Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC?
Sacher, Adrian G.
Le, Lisa W.
Leighl, Natasha B.
Coate, Linda E.
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (03) : 366 - 368

← 1 2 3 4 5 →